Inari Medical is a US-based medtech company focused on the removal of blood clots to treat pulmonary embolism and deep vein thrombosis.

Inari has developed best-in-class catheters for the treatment of venous diseases, starting with thrombectomy for deep vein thrombosis and pulmonary embolism. Inari’s unique and proprietary designs have resulted in remarkable patient outcomes which have been well-documented by peer-reviewed literature. The company grew its annual revenues from $250,000 in Q1 of 2018 to a projected $600 million in 2024.

Gilde Healthcare led Inari’s Series C financing in March 2018, motivated by the large, untapped market opportunity in venous thromboembolism and the high quality of the business’ management team. Gilde served on Inari’s Board of Directors and its Audit Committee, and worked closely with the firm across a number of different areas, including reimbursement, international expansion, and business development. Inari was publicly listed (NASDAQ: NARI) in May 2020 and has achieved a valuation in excess of $5 billion.

Bill Hoffman, former CEO of Inari: “Gilde believed in Inari at a time few other investors did.  They were an exceptional partner to Inari as we expanded our life-saving treatment throughout the US and the world.”

Geoff Pardo, General Partner at Gilde Healthcare, “Inari Medical embodies what we strive to do at Gilde- dramatically improve clinical care and outcomes in the service of patients and clinicians, while reducing the cost of care throughout the healthcare system.  Inari has also created over 1000 high quality jobs for its employees and maintains a culture of innovation, rigorous clinical study and unmatched sales execution.”

This information is accurate as of Gilde’s investment period.